ClinicalTrials.gg
RecruitingNCT06179160Updated Jul 22, 2026

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

A Phase 1 interventional study of INCB161734 and Cetuximab in Solid Tumors, sponsored by Incyte Corporation. Recruiting at 34 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Primary conditionnone(registry's first term: Colorectal Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Colorectal Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
710
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

02

Conditions studied

  • Solid Tumors

Browse trials for

Keywords

  • INCB161734
  • KRASG12D Mutation
  • pancreatic ductal adenocarcinoma (PDAC)
  • colorectal cancer (CRC)
  • non-small cell lung cancer (NSCLC)
03

In context

Lead sponsor

Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.

Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years old.
  • Locally advanced or solid tumor with KRAS G12D mutation.
  • For Part 1a and Part 2 Combination Groups 1, 2, and 7: Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, declined available therapies that are known to confer clinical benefit, or no standard available treatment to improve the disease outcome.
  • Cohort specific requirements aas defined in the protocol.
  • (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any KRAS G12D inhibitor
  • Known additional invasive within 1 year of the first dose of study drug
  • History of organ transplant, including stem cell transplantation
  • Significant, uncontrolled medical condition
  • History or presence of an abnormality
  • Inadequate organ function

Other protocol-defined Inclusion/Exclusion Criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
710 participants (estimated)

Study arms

  • Experimental
    Part 1a: Dose Escalation monotherapy

    INCB161734 at the protocol-defined dose strength based on cohort assignment.

    Drug: INCB161734

  • Experimental
    Part 1b: Dose Expansion monotherapy

    INCB161734 at the protocol-defined dose strength based on cohort assignment.

    Drug: INCB161734

  • Experimental
    Part 1c: Pharmacodynamic cohort

    INCB161734 at the protocol-defined dose strength based on cohort assignment.

    Drug: INCB161734

  • Experimental
    Part 2a: Dose Escalation combination

    INCB161734 in combination at the protocol-defined dose strength based on cohort assignment.

    Drug: INCB161734 · Drug: Cetuximab · Drug: Retifanlimab · Drug: GEMNabP · Drug: mFOLFIRINOX · Drug: FOLFOX · Drug: FOLFIRI · Drug: INCA33890

  • Experimental
    Part 2b: Dose Expansion combination

    INCB161734 in combination at the protocol-defined dose strength based on cohort assignment.

    Drug: INCB161734 · Drug: Cetuximab · Drug: Retifanlimab · Drug: GEMNabP · Drug: mFOLFIRINOX · Drug: FOLFOX · Drug: FOLFIRI · Drug: INCA33890

  • Experimental
    Part 1d: Food-Effect

    Evaluate food effect on drug exposure as defined in the protocol.

    Drug: INCB161734

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with Dose Limiting Toxicities (DLTs)

    Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.

    Time frame: Up to 28 days

  2. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug monotherapy and in combination with cetuximab and retifanlimab.

    Time frame: Up to 2 years and 90 days

  3. Number of participants with TEAEs leading to dose modification or discontinuation

    Number of participants with TEAEs leading to dose modification or discontinuation.

    Time frame: Up to 2 years and 90 days

Secondary outcomes

  1. INCB161734 pharmacokinetic (PK) in Plasma

    INCB161734 concentration in plasma.

    Time frame: Up to approximately 90 days

  2. Objective Response Rate (ORR)

    Defined as having a best overall Complete Response (CR) or Partial Response (PR), as determined by the investigator by radiographic disease assessment according to RECIST v1.1.

    Time frame: Up to 2 years

  3. Disease Control Response (DCR)

    Defined as having a best overall response of CR, PR, or Stable Disease (SD) as determined by the investigator by radiographic disease assessment according to RECIST v1.1.

    Time frame: Up to 2 years

  4. Duration of Response (DOR)

    Defined as the time from earliest date of disease response (Completed Response or Partial Response) until earliest date of disease progression as determined by the investigator by radiographic disease assessment according to RECIST v1.1 or death due to any cause if occurring sooner than progression.

    Time frame: Up to 2 years

07

Study locations

34 of 34 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2023
First posted
Dec 21, 2023
StartActual
Jan 4, 2024
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06179160
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Dec 21, 2023
Start date
Jan 4, 2024
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Jul 22, 2026

Study contacts

Incyte Corporation Call Center (US)
Contact
medinfo@incyte.com
1.855.463.3463
Incyte Corporation Call Center (ex-US)
Contact
eumedinfo@incyte.com
+800 00027423
Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KRAS G12D Inhibitor INCB161734

Start the discussion